Asembia, established in 2005, pioneered the recognition and promotion of specialty pharmacies, focusing on becoming a leader in the specialty pharmacy group purchasing organization sector. Offering scalable solutions, including prescription...
Asembia, established in 2005, pioneered the recognition and promotion of specialty pharmacies, focusing on becoming a leader in the specialty pharmacy group purchasing organization sector. Offering scalable solutions, including prescription...
As manufacturers gain real-world experience with Inflation Reduction Act price negotiations, early lessons from the first 3 cycles highlight the need for earlier planning, stronger cross-functional coordination, and new approaches to data,...
As manufacturers gain real-world experience with Inflation Reduction Act price negotiations, early lessons from the first 3 cycles highlight the need for earlier planning, stronger cross-functional coordination, and new approaches to data,...
At Asembia 2026, market access leaders warned that sweeping policy shifts—from most favored nation (MFN) pricing and Inflation Reduction Act (IRA) negotiations to pharmacy benefit manager (PBM) and 340B reform—are reshaping global pricing...
At Asembia 2026, market access leaders warned that sweeping policy shifts—from most favored nation (MFN) pricing and Inflation Reduction Act (IRA) negotiations to pharmacy benefit manager (PBM) and 340B reform—are reshaping global pricing...
At Asembia 2026, speakers highlighted how embedding specialty pharmacy care coaches into diabetes management at UMass Memorial Health is improving outcomes, reducing costs, and advancing value-based care by addressing both clinical and social...
At Asembia 2026, speakers highlighted how embedding specialty pharmacy care coaches into diabetes management at UMass Memorial Health is improving outcomes, reducing costs, and advancing value-based care by addressing both clinical and social...
At Asembia 2026, Dee Chaudhary, Principal, Commercial Strategy Consulting Life Sciences and Healthcare, Clarivate, outlined how the Inflation Reduction Act (IRA), renewed Most Favored Nation (MFN)-style pricing pressure, and broader coverage...
At Asembia 2026, Dee Chaudhary, Principal, Commercial Strategy Consulting Life Sciences and Healthcare, Clarivate, outlined how the Inflation Reduction Act (IRA), renewed Most Favored Nation (MFN)-style pricing pressure, and broader coverage...
As the 2026 midterm elections approach, the health policy landscape faces major uncertainty. This panel will explore how potential changes to congressional power-balance and state dynamics could shape key priorities like drug pricing,...
As the 2026 midterm elections approach, the health policy landscape faces major uncertainty. This panel will explore how potential changes to congressional power-balance and state dynamics could shape key priorities like drug pricing,...
Asembia 2024 speakers Olivia Banyon and Sean McCabe discuss the concept of value-based care, patient-centered care, clinician well-being, and system workflows to improve the quality of life for patients.
Asembia 2024 speakers Olivia Banyon and Sean McCabe discuss the concept of value-based care, patient-centered care, clinician well-being, and system workflows to improve the quality of life for patients.
Asembia 2024 speaker Bill McElnea discusses the role of health system specialty pharmacies in reducing total cost of care, enhancing medication adherence, and improving outcomes under value-based care arrangements.
Asembia 2024 speaker Bill McElnea discusses the role of health system specialty pharmacies in reducing total cost of care, enhancing medication adherence, and improving outcomes under value-based care arrangements.
Patient services emerged as a central topic at AXS24, with many stakeholders emphasizing the need for consistency and accessibility in patient support. They also highlighted the importance of addressing both financial and emotional support...
Patient services emerged as a central topic at AXS24, with many stakeholders emphasizing the need for consistency and accessibility in patient support. They also highlighted the importance of addressing both financial and emotional support...
A national study presented at AASLD 2026 found that semaglutide was associated with a 16% lower risk of liver fibrosis progression compared with dipeptidyl peptidase-4 inhibitors among veterans with metabolic dysfunction-associated steatotic...
A national study presented at AASLD 2026 found that semaglutide was associated with a 16% lower risk of liver fibrosis progression compared with dipeptidyl peptidase-4 inhibitors among veterans with metabolic dysfunction-associated steatotic...
A real-world study presented at AASLD 2026 found that semaglutide was associated with greater reductions in liver enzymes, body weight, and hemoglobin A1c than resmetirom among patients with metabolic dysfunction-associated steatohepatitis,...
A real-world study presented at AASLD 2026 found that semaglutide was associated with greater reductions in liver enzymes, body weight, and hemoglobin A1c than resmetirom among patients with metabolic dysfunction-associated steatohepatitis,...
A study presented at AASLD TLM 2026 found that a PharmD-led sub-clinic improved access to semaglutide and facilitated timely treatment initiation among patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
A study presented at AASLD TLM 2026 found that a PharmD-led sub-clinic improved access to semaglutide and facilitated timely treatment initiation among patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
Roy Moore discusses emerging chronic kidney disease therapies, the impact of generic competition, and how clinical evidence, treatment costs, and reimbursement considerations may shape payer decisions and patient access.
Roy Moore discusses emerging chronic kidney disease therapies, the impact of generic competition, and how clinical evidence, treatment costs, and reimbursement considerations may shape payer decisions and patient access.
Hamad Husainy, DO, FACEP, discusses opportunities to strengthen care transitions, improve data sharing, and reduce avoidable emergency department visits and hospital readmissions.
Hamad Husainy, DO, FACEP, discusses opportunities to strengthen care transitions, improve data sharing, and reduce avoidable emergency department visits and hospital readmissions.
In this interview, Travis Morgan, CPA, MBA, discusses how a pharmacist-led medication optimization program targeting polypharmacy among Medicare accountable care organization beneficiaries was associated with increasing reductions in total...
In this interview, Travis Morgan, CPA, MBA, discusses how a pharmacist-led medication optimization program targeting polypharmacy among Medicare accountable care organization beneficiaries was associated with increasing reductions in total...
In this interview, Rakshith Yashvanth discusses how health plans can move SDOH programs beyond referrals by strengthening community partnerships, reducing administrative burden, and using linked data to measure service delivery and long-term...
In this interview, Rakshith Yashvanth discusses how health plans can move SDOH programs beyond referrals by strengthening community partnerships, reducing administrative burden, and using linked data to measure service delivery and long-term...
In this interview, Colby Catania, MS, the managing director at Houlihan Lokey, discusses how investments in infusion providers are shaping the pharmaceutical market, with advice for providers and investors on how to navigate the market and...
In this interview, Colby Catania, MS, the managing director at Houlihan Lokey, discusses how investments in infusion providers are shaping the pharmaceutical market, with advice for providers and investors on how to navigate the market and...
In this interview, a guest expert shares insights discussed at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting about the updated ASCO Living Guideline for multiple myeloma, including broader use of quadruplet regimens,...
In this interview, a guest expert shares insights discussed at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting about the updated ASCO Living Guideline for multiple myeloma, including broader use of quadruplet regimens,...
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving...
07/21/2026
First Report Managed Care
Asembia is an industry leader in the specialty pharmacy sector. It aims to connect and strengthen the pharmaceutical industry and transform its ideas into significant innovations, all dedicated to optimizing and improving patients' experiences worldwide. Visit asembia.com for more information.
